

# EVOcells Oncology: tailored genetic engineering of iPSC-derived immune effector cells and combination with the right biologic therapeutics result in optimal killing of primary tumor cells from patients

Michael Esquerré<sup>1</sup>, Audrey Holtzinger<sup>2</sup>, Nadja Wagner<sup>3</sup>, Monika Braun<sup>3</sup>, Mélanie Pichery<sup>1</sup>, Stefanie Pfaender<sup>2</sup>, Stephanie Sontag<sup>2</sup>, Kathrin Haake<sup>2</sup>, Michela Mirenda<sup>1</sup>, Davide Grandolfo<sup>2</sup>, Chloé Beuraud<sup>1</sup>, Mandy Richter<sup>2</sup>, Philip Hublitz<sup>2</sup>, Julien Bousquet<sup>1</sup>, Marion Fabre<sup>1</sup>, Mylène Gador<sup>1</sup>, Delphine Betous<sup>1</sup>, Tanja Schneider<sup>2</sup>, Oriane Bombarde<sup>1</sup>, Camille Esquerré<sup>1</sup>, Loïc Ysebaert<sup>4</sup>, Fabien Despas<sup>4</sup>, Michael Paillasse<sup>1</sup>, Daniel Sommermeyer<sup>3</sup>, Matthias Austen<sup>2</sup>, Andreas Scheel<sup>2</sup> & Markus Dangl<sup>3</sup>



1Evotec, Toulouse, France; 2Evotec, Göttingen, Germany; 3Evotec, Munich, Germany; 4Oncopole (IUCT-O), Toulouse, France



## Abstract: 3203







Cell therapy GMP manufacturing site to deliver clinical candidates